TELA Bio Announces U.S. Commercial Launch of SiteGuard™ No Rinse Antimicrobial Solution

Company expands product portfolio with focus on addressing surgical site infections in plastic reconstructive surgery

 

MALVERN, Pa., March 03, 2022 (GLOBE NEWSWIRE) — TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced the commercial launch of its SiteGuard No Rinse Antimicrobial Solution for use in plastic reconstructive surgery.
 
SiteGuard utilizes Next Science’s proprietary XBIO® Technology that supports surgical site and post-operative infection control by addressing the biofilms that make bacteria more resistant to traditional antimicrobial agents, disinfectants, and host immune defenses. XBIO Technology deconstructs biofilm, destroys the bacteria enveloped in the solution, and defends against bacterial recolonization. There is no known bacterial resistance to XBIO Technology, and the no-rinse delivery allows the solution to provide over five hours of ongoing protection against bacterial biofilms with exceptional rates of pathogen removal.
 
“SiteGuard is a complementary technology that we believe enhances our mission to deliver a portfolio of next-generation soft-tissue solutions that are both clinically effective and economically impactful,” said Antony Koblish, President and CEO of TELA Bio. “Early test market experience with SiteGuard has been encouraging, and we look forward to broadening awareness and usage of the technology nationwide.” … read more